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Background: Type 1 diabetes can be treated by the transplantation of cadaveric whole pancreata or isolated
pancreatic islets. However, this form of treatment is hampered by the chronic shortage of cadaveric donors.
Embryonic stem (ES) cell-derived insulin producing cells (IPCs) offer a potentially novel source of unlimited cells for
transplantation to treat type 1 and possibly type 2 diabetes. However, thus far, the lack of a reliable protocol for
efficient differentiation of ES cells into IPCs has hindered the clinical exploitation of these cells.
Methods: To efficiently generate IPCs using ES cells, we have developed a double transgenic ES cell line
R1Pdx1AcGFP/RIP-Luc that constitutively expresses pancreatic β-cell-specific transcription factor pancreatic and
duodenal homeobox gene 1 (Pdx1) as well as rat insulin promoter (RIP) driven luciferase reporter. We have
established several protocols for the reproducible differentiation of ES cells into IPCs. The differentiation of ES cells
into IPCs was monitored by immunostaining as well as real-time quantitative RT-PCR for pancreatic β-cell-specific
markers. Pancreatic β-cell specific RIP became transcriptionally active following the differentiation of ES cells into
IPCs and induced the expression of the luciferase reporter. Glucose stimulated insulin secretion by the ES
cell-derived IPCs was measured by ELISA. Further, we have investigated the therapeutic efficacy of ES cell-derived
IPCs to correct hyperglycemia in syngeneic streptozotocin (STZ)-treated diabetic mice. The long term fate of the
transplanted IPCs co-expressing luciferase in syngeneic STZ-induced diabetic mice was monitored by real time
noninvasive in vivo bioluminescence imaging (BLI).
Results: We have recently demonstrated that spontaneous in vivo differentiation of R1Pdx1AcGFP/RIP-Luc ES
cell-derived pancreatic endoderm-like cells (PELCs) into IPCs corrects hyperglycemia in diabetic mice. Here, we
investigated whether R1Pdx1AcGFP/RIP-Luc ES cells can be efficiently differentiated in vitro into IPCs. Our new data
suggest that R1Pdx1AcGFP/RIP-Luc ES cells efficiently differentiate into glucose responsive IPCs. The ES cell
differentiation led to pancreatic lineage commitment and expression of pancreatic β cell-specific genes, including
Pax4, Pax6, Ngn3, Isl1, insulin 1, insulin 2 and PC2/3. Transplantation of the IPCs under the kidney capsule led to
sustained long-term correction of hyperglycemia in diabetic mice. Although these newly generated IPCs effectively
rescued hyperglycemic mice, an unexpected result was teratoma formation in 1 out of 12 mice. We attribute the
development of the teratoma to the presence of either non-differentiated or partially differentiated stem cells.
Conclusions: Our data show the potential of Pdx1-engineered ES cells to enhance pancreatic lineage commitment
and to robustly drive the differentiation of ES cells into glucose responsive IPCs. However, there is an unmet need
for eliminating the partially differentiated stem cells.
Keywords: Bioluminescence imaging, Embryonic stem cells, Diabetes, Differentiation, Hyperglycemia, Insulin
producing cells, Luciferase, Pancreatic and duodenal homeobox gene 1, Transplantation, Teratoma* Correspondence: sudhanshu-raikwar@uiowa.edu
Department of Internal Medicine, Division of Immunology, Roy J. and Lucille
A. Carver College of Medicine, University of Iowa and Iowa City Veterans
Affairs Medical Center, Building 41, Room #128, 601 Highway 6W, Iowa City,
IA 52246, USA
© 2012 Raikwar and Zavazava; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Raikwar and Zavazava Transplantation Research 2012, 1:19 Page 2 of 11
http://www.transplantationresearch.com/content/1/1/19Background
Type 1 diabetes is an autoimmune disease that can be
surgically corrected by the transplantation of either the
whole pancreas or that of pancreatic islets [1-4]. How-
ever, chronic shortage of organ donors, lifelong im-
munosuppressive therapy and chronic graft rejection
currently limit the therapeutic potential of both options.
Ultimately, chronic graft rejection leads to insulin de-
pendence and the development of serious diabetic com-
plications [5-10]. With the incidence of diabetes
increasing at an alarming rate worldwide, there is an ur-
gent and compelling need to develop novel treatment
approaches. In this regard, embryonic stem (ES) cells
and the recently developed induced pluripotent stem
(iPS) cells potentially offer a novel alternative for the de-
velopment of stem cell-based therapies [11-13]. How-
ever, the generation of functional insulin producing cells
(IPCs) from ES or iPS cells has been rather inefficient;
thus there is a need to improve on the protocols for the
differentiation process.
Published work by others appeared to suggest that it is
feasible to directly differentiate ES cells into IPCs [14].
Unfortunately, this work has remained irreproducible in
many laboratories around the world. During embryonic
development, a wide variety of transcription factors, in-
cluding Pdx1, Ngn3, NeuroD, MafA, MafB, Gata4,
Gata6, Ptf1a and Pax4 are involved in pancreatic β cell
development and function. Pdx1 is the master regulator
of pancreatic development [15-18] during embryogen-
esis, β cell differentiation [16,19-21] and is essential for
the maintenance of β-cell function in the adults
[15,16,22,23]. Mutations in the Pdx1 coding sequence in
humans and mice lead to failure of the pancreatic
organ to develop [25]. Here, we hypothesized that pan-
creatic lineage commitment of ES cells by pancreatic β
cell-specific transcription factor Pdx1 enhances the gen-
eration of IPCs, thereby providing an unlimited source of
cells for the treatment of diabetes. The rationale under-
lying this approach is that expression of pancreatic β
cell-specific transcription factor Pdx1 will maximize the
pancreatic lineage commitment and differentiation of ES
and iPS cells into IPCs [15,17,26-31]. To facilitate greater
efficiency of the generation of IPCs from ES cells, we have
generated a double transgenic ES cell line R1Pdx1AcGFP/
RIP-Luc to stably express an in-frame Pdx1AcGFP fusion
protein [32]. Here, we describe the generation of IPCs
in vitro using ES cells ectopically expressing Pdx1. For the
real-time non-invasive in vivo bioluminescence imaging
(BLI), we engineered a rat insulin promoter (RIP) driven
luciferase reporter to monitor the fate and function of the
IPCs post transplantation. Further, we show that trans-
plantation of ES cell-derived IPCs efficiently corrects
hyperglycemia in diabetic mice. However, the lack of cell
surface markers specific for IPCs raises the potential forteratoma formation by residual non-differentiated ES cells.
These studies justify the need to develop novel strategies




We have recently described the generation and char-
acterization of the double transgenic mouse ES cell line
R1Pdx1AcGFP/RIP-Luc stably expressing an in-frame
Pdx1AcGFP fusion protein and RIP driven luciferase
reporter in detail elsewhere [32]. The R1Pdx1AcGFP/RIP-
Luc mouse ES cell line was maintained in DMEM contain-
ing 1,000 IU/ml leukemia inhibitory factor (LIF, ESGRO,
ESG1107, Chemicon International Inc. Millipore, Billerica,
MA, USA) and 15% fetal bovine serum (FBS), on primary
murine embryonic fibroblast feeder layer as described
earlier [33].
In vitro differentiation of ES cells into IPCs
We tested the in vitro differentiation of the
R1Pdx1AcGFP/RIP-Luc ES cell line to generate glucose
responsive IPCs using four modified protocols as
depicted in Figure 1a as follows: (A) Undifferentiated
R1Pdx1AcGFP/RIP-Luc ES cells were subjected to dif-
ferentiation using a multi-step protocol [14]. Briefly, ac-
tively proliferating R1Pdx1AcGFP/RIP-Luc ES cells were
trypsinized and 1 × 107 cells were plated on to ultra-low
attachment culture dishes in the presence of freshly pre-
pared (45 μl/50 ml) 1:10 α-Monothioglycerol (Sigma
Chemical Company, St. Louis, MO, USA) to promote
embryoid body (EB) formation for four days (Figure 1a).
The EBs were trypsinized and grown in serum-free
DMEM supplemented with ITS-G (Invitrogen, Carlsbad,
CA, USA) and enriched for nestin+ cells for nine days.
The nestin+ cells were grown in DMEM/F12 (1:1)
medium supplemented with 25 ng/ml bFGF (R&D Sys-
tem, Inc., Minneapolis, MN, USA), N2, B27, 10 ng/ml
EGF and KGF supplements and cultured for eight days.
The endocrine precursors obtained at the end of this
stage were further propagated in low glucose DMEM
supplemented with N2, B27 and 10 mM Nicotinamide
to enrich IPCs for 12 days. (B) Day 4 EBs were cultivated
in serum free DMEM with ITS-G (Invitrogen) for nine
days followed by differentiation for six days in the pres-
ence of N2, B27, laminin and Exendin 4 and then similar
to protocol A. (C) Day 4 EBs were cultivated in serum
free DMEM similar to protocol A for nine days but
without ITS-G. Subsequently the cells were cultured for
12 days as in protocol A. We also developed a new
protocol (D) which completely eliminates the enrich-
ment of the nestin+ cells. In the new protocol, the Day 4
EBs were directly cultivated in DMEM supplemented
with 10% FBS for six days. The resulting cell population
Figure 1 Pdx1 promotes ES cell-differentiation into IPCs. (a) Schematic representation of the ES cell differentiation protocols. (b) ES cells
were subjected to differentiation using a multi-step differentiation protocol. The Pdx1 expressing R1Pdx1AcGFP/RIP-Luc ES cells (20X
magnification) were subjected to EB formation followed by differentiation using four different protocols. Immunostaining of ES cell-derived IPCs
for pancreatic markers: The Pdx1 expressing ES cell-derived differentiating cells and IPCs using protocol D were characterized by confocal
microscope (60X magnification) following immunostaining using Foxa2, Sox17, Ngn3, NeuroD, insulin, somatostatin, glucagon and C-peptide. The
results indicate that the differentiating cells express Foxa2, Sox17, Ngn3, and NeuroD which are critical for the development of IPCs. The
differentiation leads to the generation of IPCs and glucagon expressing isolated cell clusters. As compared to the IPCs there is an abundance of
glucagon expressing cells. (c) The in vitro differentiation of R1Pdx1AcGFP/RIP Luc ES cells into IPCs was monitored by real-time quantitative RT-
PCR at various stages of differentiation. As a positive control, 18S rRNA was used to normalize and validate the results. The data indicate
progressive up-regulation of Foxa2, Isl1, Pax4, glucagon, insulin 1, insulin 2 and PC2/3 genes following the differentiation of ES cells into IPCs.
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in the presence of N2, B27 and 10 mM nicotinamide for
13 days.
Analysis of gene expression
To determine gene expression profiles at various stages of
differentiation, total RNA was isolated from undifferenti-
ated ES cells, EBs, proendocrine precursors, endocrine
precursors and IPCs using the Absolute RNA Miniprep
Kit (Stratagene, La Jolla, CA, USA) as per the instructions
provided by the manufacturer. The cDNA synthesis was
performed by reverse transcription using Stratascript
QPCR cDNA synthesis kit (Stratagene) using the follow-
ing conditions: Primer annealing at 25°C for 5 minutes,
cDNA synthesis at 42°C for 45 minutes followed by reac-
tion termination at 95°C. Real-time quantitative RT-PCRfor various genes and the control 18S rRNA was per-
formed with Brilliant SYBR Green QPCR master mix
(Stratagene) with the following conditions: 1 denaturation
cycle for 10 min at 95°C followed by 30-40 cycles (15-25
cycles for 18S rRNA) of 30 seconds denaturation, 1 mi-
nute annealing at 55-60°C and 1 minute extension at 72°C.
The number of cycles, annealing temperature and ex-
tension time were optimized for the abundance of the
transcripts, the Tm of the primers and the size of the
amplicons. All reactions were performed in a Mx3000p
Multiplex Quantitative PCR system (Stratagene). The dis-
sociation curves were generated for all samples and the
relative gene expression was normalized with the control
18S rRNA. The threshold cycle Ct value was determined
as described [34]. Real-time quantitative RT-PCR reactions
were performed multiple times to validate our results
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tative results of the real-time quantitative RT-PCR fol-
lowing ES cell differentiation using protocol D are
presented in Figure 1c since the IPCs generated using
the protocol D consistently expressed the highest levels
of insulin.
Immunostaining and immunohistochemistry
The ES cells grown on chambered glass slides were dif-
ferentiated using the highly efficient protocol D and
were fixed at different stages of differentiation with 2%
paraformaldehyde, quenched in PBS containing 30 mM
glycine and permeabilized with 0.1% Triton X-100 for 30
minutes at RT and blocked for 2 hours in PBS contain-
ing 2% Bovine Serum Albumin fraction V. The cells
were stained with primary antibodies (1:250 dilution)
against Ngn3 (SC-13794, goat polyclonal IgG, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), Foxa2 (SC-
6554, goat polyclonal IgG, Santa Cruz Biotechnology),
Sox17 (SC-17356, goat polyclonal IgG, Santa Cruz Bio-
technology), glucagon (SC-13091, rabbit polyclonal IgG,
Santa Cruz Biotechnology), somatostatin (SC-20999,
rabbit polyclonal IgG, Santa Cruz Biotechnology) insulin
(SC-7838, goat polyclonal IgG, Santa Cruz Biotechnology)
and C-peptide (4593, rabbit polyclonal IgG, Cell Signaling
Technology, Inc., Danvers, MA, USA), respectively. The
cells were visualized by the use of either the Alexa Fluor
488 conjugated donkey anti-rabbit (A21206, Molecular
Probes, Invitrogen,) or Alexa Fluor 546 conjugated don-
key anti-goat (A11056, Molecular Probes, Invitrogen)
secondary antibodies (1:500 dilution) and Vectashield
mounting medium with DAPI (H1200, Vector laboratories,
Inc. Burlingame, CA, USA). Multiphoton imaging was per-
formed either on Radience 2100MP multiphoton micro-
scope (Bio-Rad Laboratories, Hercules, CA, USA) or Zeiss














18S rRNA 50TAACGAACGAGACTCTGGCAT3Microimaging GmbH, Jena, Germany) using 60X oil
immersion objective lens and the images were captured as
grayscale pictures and processed using the Image J
program (National Institutes of Health) or ZEN Lite 2011
software (Carl Zeiss Microimaging GmbH, Jena, Germany).
Immunohistochemical analysis and hematoxylin-eosin
staining of the tissue sections was performed as described
elsewhere [32].
Measurement of insulin by ELISA
To test the glucose stimulated insulin secretion by ES
cell-derived IPCs we used Mercodia Ultrasensitive
Mouse Insulin ELISA, a solid phase two-site enzyme im-
munoassay (Mercodia, Inc., Winston Salem, NC, USA)
[27]. This ELISA is a direct sandwich ELISA in which
two distinct monoclonal antibodies are directed against
two separate antigenic determinants on the insulin mol-
ecule. To measure insulin secretion by the ES cell-
derived IPCs using different protocols, the cell culture
supernatants in triplicates from 1 × 106 ES cell-derived
IPCs plated in six-well plates were collected 24 hours
after changing the medium and were directly assayed
using the mouse ultrasensitive insulin ELISA kit
(Mercodia, Inc) and the values obtained were repre-
sented as insulin secretion (ng/mg) after normalizing
to the total protein content (Protein assay reagent,
Bio-Rad Laboratories).
For glucose stimulated insulin secretion studies, the
cell culture supernatants in triplicates were collected
from 5 × 104 ES cell-derived IPCs that were plated in
24-well plates and incubated in KRBH buffer pH 7.4
(NaCl 118.4 mM, KCl 4.7 mM, KH2PO4 1.2 mM, CaCl2
2.4 mM, MgSO4 1.2 mM, NaHCO3 20 mM and HEPES
10 mM) in the presence of low glucose (2.8 mM) or high
glucose (20 mM) and either with agonist tolbutamide
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cell culture supernatant reacts with the peroxidase-
conjugated anti-insulin antibodies and anti-insulin anti-
bodies bound to the microplate well. Subsequent
washing removes unbound enzyme labeled antibody. The
bound conjugate is detected by a reaction with 3,305,50-
tetramethylbenzidine. The reaction is finally terminated
by adding acid to give a colorimetric endpoint which is
analyzed by an ELISA plate reader. The values obtained
were represented as insulin secretion (ng/ml/hour).
Mice
All animal experiments were approved and performed
according to International Animal Care and Use Com-
mittee (IACUC) guidelines. The University of Iowa ani-
mal vivarium is accredited by the Association for the
Assessment and Accreditation of Laboratory Animal
Care (AAALAC). Eight week-old 129/SvJ mice (Jackson
Laboratory, Bar Harbor, ME, USA) were used for the
syngeneic transplantation experiments. Diabetes was
induced by five consecutive intraperitoneal streptozoto-
cin (STZ) (EMD Millipore Corporation, Billerica, MA<
USA) injections (50 mg/Kg body weight). STZ was
reconstituted in ice cold fresh sodium citrate buffer (pH
4.5) immediately prior to injection. The fasting blood
glucose levels were regularly monitored using a Hemo-
Cue glucose 201 analyzer (HemoCue AB, Ängelholm,
Sweden). Mice with blood glucose levels >350 mg/dl for
two consecutive readings that were five days apart were
considered diabetic. Diabetic 129/SvJ mice do not sur-
vive beyond 15 days due to severe hyperglycemia. Ap-
proximately 1 × 106 R1Pdx1AcGFP ES cell-derived IPCs
were transplanted under the kidney capsule of the dia-
betic mice.
Real-time noninvasive in vivo bioluminescence imaging
(BLI)
The in vivo fate and function of the transplanted IPCs
was monitored using real-time noninvasive in vivo BLI.
The Xenogen IVIS Imaging System 200 Series (Caliper
Life Sciences, Hopkinston, MA, USA) was used in these
experiments as described elsewhere [32].
Statistical analysis
The experimental data were analyzed using the Graph-
Pad Prism 5 software (GraphPad Software, Inc., San
Diego, CA, USA). The data were tested for significance
with Student’s t-test or one-way ANOVA where applic-
able. In all cases, *P <0.05 was considered significant.
Results
ES cell-derived IPCs secrete insulin
The results from multiple earlier studies have indicated
low insulin secretion by ES cell-derived IPCs [27,35-39].Since Pdx1 is a major transcription factor for the devel-
opment of the pancreas as well as pancreatic β cells, we
reasoned that generating a stable Pdx1-expressing ES
cell line R1Pdx1AcGFP/RIP-Luc and directing its differ-
entiation towards IPCs could increase the yield of IPCs.
To investigate which approach was more effective at
generating IPCs, four different differentiation protocols
as described in the methods section and depicted in
Figure 1a were studied. The progressive differentiation
of the R1Pdx1AcGFP/RIP-Luc ES cell line into IPCs was
monitored by immunostaining for various pancreatic
markers (Figure 1b). As expected the differentiation
process led to the expression of insulin producing cell
clusters. Our immunostaining results using the differen-
tiation protocol D indicate that the cells express Foxa2,
Sox17, Ngn3 and NeuroD markers during the early steps
of differentiation (Figure 1b). In addition to C-peptide
and insulin expressing cells, we found that a significant
cell population expressed glucagon. The newly generated
IPCs were organized into small islet-like clusters
(Figure 1b). Based on immunostaining results, we esti-
mated that approximately 25 to 30% of the cells were
expressing insulin. To further confirm that the cells had
differentiated into pancreatic lineage, the expression of
various pancreatic genes was studied. We used real-time
quantitative RT-PCR analysis on RNA isolated from the
cells at the completion of various stages to monitor the
in vitro differentiation of ES cells into IPCs (Figure 1c).
The RT-PCR results from a representative differentiation
using protocol D indicate a progressive up-regulation of
pancreatic β-cell-specific genes commensurate with the
differentiation status of the ES cells. A significant up-
regulation of Foxa2, Pax4, insulin 1, insulin 2, PC2/3
and glucagon gene expression in the IPCs was observed.
The insulin production by ES cell-derived IPCs was
determined by an ultrasensitive ELISA. The ELISA
results indicate that the ES cell-derived IPCs robustly se-
crete insulin (Figure 2a). The protocols A to C have
slight variations but include the nestin selection stage
while protocol D is devoid of the nestin selection stage.
Our ELISA data suggest that elimination of the nestin
selection stage (protocol D) significantly enhances the
generation of IPCs as well as improves insulin secretion
(Figure 2a). Further, we tested the glucose responsive in-
sulin secretion by the IPCs in the presence of low and
high glucose as well as low glucose plus agonist tolbuta-
mide and high glucose plus antagonist nifedipine
(Figure 2b). In the presence of low glucose, the insulin
secretion is very low and marginally increases in the
presence of the agonist tolbutamide. However, in the
presence of high glucose the insulin secretion is com-
paratively higher and in the presence of high glucose
and the antagonist nifedipine the insulin secretion is sig-
nificantly inhibited as expected. These results confirm
Figure 2 Pdx1 expressing ES cell-derived IPCs are glucose responsive. (a) Insulin secretion by 1 × 106 IPCs plated in triplicates in six-well
plates and generated using all the four differentiation protocols was evaluated by ELISA and expressed relative to the protein content of the cells.
The results indicate that generation of IPCs using protocol D by eliminating the nestin selection stage significantly improves the generation of
IPCs. The values represent mean ± SD (n = 3) where ***P <0.0001 vs other groups by one-way ANOVA with Tukey’s multiple pairwise
comparison. (b) For testing glucose stimulated insulin secretion, 5 × 104 IPCs were plated in 24-well plates in triplicates in the presence of
2.8 mM glucose (LG), 2.8 mM glucose + 100 μM tolbutamide (LG + TB), 20 mM glucose (HG) or 20 mM glucose + 50 μM nifedipine (HG + NI).
The insulin secretion was monitored by an ultrasensitive ELISA. The values represent mean ± SE (n = 3) and all data were tested for significance
with Student’s t-test or one way ANOVA where applicable. In all cases, *P <0.05 was considered statistically significant.
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sponsive. All experiments discussed hereafter were per-
formed with the IPCs generated following differentiation
with protocol D.
ES cell-derived IPCs significantly reduce hyperglycemia
To determine whether R1Pdx1AcGFP/RIP-Luc ES cell-
derived IPCs correct hyperglycemia in diabetic mice, 1 ×
106 IPCs were transplanted under the kidney capsule in
STZ-induced diabetic syngeneic 129/SvJ mice. Healthy
mice have a fasting serum glucose level of about 105 ±
10 mg/dl. In contrast, our diabetic mice had elevated
glucose levels in the range of 500 to 650 mg/dl. The IPC
treatment group comprised of 12 mice while normal
non-diabetic as well as STZ treated control group com-
prised of 5 mice each. Blood glucose levels were mea-
sured prior to IPCs transplantation and every three to five
days post-IPCs transplantation. The STZ-treated diabetic
control mice exhibited elevated blood glucose levels
(>600 mg/dl), polyuria, weight loss, muscle wasting,
hunched back posture, poor mobility, soiled body coat
color, shivering and died within 14 days. The IPCs trans-
planted mice showed remarkable correction of the hyper-
glycemia as early as Day 15 post-transplantation. Further,
these mice continued to exhibit near normoglycemic
blood glucose levels beyond 40 days post-transplantation
(Figure 3a). The Day 40 blood glucose values for the
IPCs-treated mice reached the lower threshold of 250
mg/dl (mean 243.8 (95% CI 216.2 to 271.4)) remaining
higher than that of control mice. Although complete cor-
rection of blood glucose levels was not observed, the IPC
transplanted mice survived for >150 days post IPCtransplantation. This finding suggests that our IPCs were
not capable of fully reducing the blood glucose levels.
With a significant improvement in the blood glucose
levels, the IPC transplanted mice displayed improved feed
consumption, improved posture, increase in body
weights, reduced urination frequency, lack of shivering,
improved mobility, shiny body coat color and survival
throughout the duration of the study. To confirm that the
IPCs transplanted under the kidney capsule were indeed
responsible for the correction of hyperglycemia, the kid-
ney sections from the nephrectomized mice were sub-
jected to immunostaining using anti-insulin antibody.
Our immunostaining results (Figure 3b) confirm the pres-
ence of insulin expressing cells in the transplanted kidney.
Finally, to rule out the possibility of endogenous pancre-
atic β cell regeneration, we performed hematoxylin-eosin
staining of the pancreas on Day 150 from the STZ treated
mice that were transplanted with IPCs. Our histopath-
ology data (Figure 3c) demonstrates that the normal pan-
creas has extremely large pancreatic islets. However, the
pancreas from the mice transplanted with IPCs revealed
near complete loss of pancreatic islets and no evidence of
endogenous pancreatic β-cell regeneration. Taken to-
gether, our data suggest that ES cell-derived IPCs were in-
deed responsible for the long-term survival and
correction of the diabetic phenotype post-transplantation
in the diabetic mice.
In vivo imaging of the IPCs using real-time noninvasive
bioluminescence imaging (BLI)
One of the major caveats in the field of islet transplant-
ation is the inability to successfully and noninvasively
Figure 3 R1Pdx1AcGFP ES cell-derived IPCs correct hyperglycemia in diabetic mice. (a) The therapeutic efficacy of R1Pdx1AcGFP/RIP-Luc ES
cell-derived IPCs was evaluated following transplantation under the kidney capsule of syngeneic 129/SvJ mice (n = 12) rendered diabetic by
streptozotocin (STZ) treatment. The blood glucose levels continued to decline beyond Day 15 post-transplantation and stabilized thereafter.
Normal nondiabetic mice (n = 5) and STZ-treated 129/SvJ mice (n = 5) were used as appropriate controls for comparing the blood glucose levels.
As early as Day 15 and throughout the duration of the study, the blood glucose levels of mice transplanted with IPCs were significantly lower
compared to the STZ-treated mice. The data were analyzed by one-way ANOVA and are presented as mean ± SD, ***P <0.0001, using Tukey’s
pairwise multiple comparison for Day 15. (b) The kidney bearing the transplanted IPCs was evaluated for insulin expression by immunostaining
using an anti-insulin antibody. The results indicate the localized presence of ES cell-derived insulin expressing cells. (c) Control mouse pancreas
and the pancreas from IPCs transplanted mice 150 days post transplantation were examined by hematoxylin-eosin staining. Unlike control
pancreas from non-diabetic mouse, the IPCs transplanted streptozotocin-treated diabetic mouse pancreas did not show any evidence of
pancreatic beta cell regeneration.
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We reasoned that incorporation of a tissue-specific pro-
moter into the IPCs to drive the expression of luciferase
reporter would enable us to noninvasively monitor their
long-term survival and function in vivo. This was
achieved by engineering RIP driven luciferase reporter in
the undifferentiated R1Pdx1AcGFP-expressing ES cells
[32]. In the undifferentiated state, the RIP is transcrip-
tionally inactive as determined by the luciferase assay.
However, in the R1Pdx1AcGFP/RIP-Luc ES cell-derived
IPCs, the RIP becomes transcriptionally active and drives
a high level expression of the luciferase gene. Real time
in vivo BLI of the mice transplanted with R1Pdx1AcGFP
ES cell-derived IPCs revealed a progressive increase in
the luciferase activity with time (Figure 4a). However, in
1 of the 12 transplanted mice, BLI signal intensity con-
tinued to increase in size as well as magnitude beyond
30 days post-transplantation. We further followed this
observation by repeating BLI on Day 50 post-transplant-
ation. At this time point, the BLI signal intensity was
saturated and dispersed beyond the transplanted area
(Figure 4a). To investigate the underlying reason, wesacrificed this mouse at Day 52 and performed necropsy.
We discovered that the transplanted IPCs had formed a
large teratoma in the kidney (Figure 4b). This finding, al-
though not entirely surprising, indicated that some of
the ES cells remained in the non-differentiated state or
were only partially differentiated and formed teratomas.
Prior to transplantation, non-differentiated cells could
not be removed due to a lack of β-cell-specific surface
markers to selectively enrich the IPCs.
Histopathological examination of the teratoma
revealed the presence of epidermoid, mucous secreting,
ciliated epithelial as well as neuronal cells (Figure 4c). Fi-
nally, to confirm the presence of IPCs in the kidney
bearing teratoma, immunostaining was performed. Insu-
lin staining cells were detectable (Figure 4d) in the kid-
ney containing IPCs but not in control kidneys from the
contra-lateral side, suggesting that the transplanted cells
were producing insulin under the renal capsule. Taken
together, our results highlight the potential of ES cells to
generate IPCs that can be used therapeutically. However,
the differentiation process is not yet optimal since one
of the IPC-transplanted mouse developed a teratoma.
Figure 4 Pdx1 expressing ES cell-derived IPCs cause teratoma formation. (a) The long-term fate of the IPCs transplanted under the renal
capsule in diabetic mice was monitored by real-time noninvasive bioluminescence imaging (BLI). Our ES cells were engineered using rat insulin
promoter (RIP) driven luciferase reporter. Following differentiation of the ES cells, the transcriptional activation of the RIP leads to a selective
robust expression of luciferase in the IPCs. In one of the IPC transplanted mouse, the BLI signal showed a progressive increase, especially beyond
Day 40 post-transplantation with maximum BLI signal intensity at Day 50 post-transplantation. (b) The mouse transplanted with ES cell-derived
IPCs was sacrificed and the internal organs were examined. The kidney bearing the transplanted IPCs revealed the presence of teratoma
formation covering the dorsal and ventral sides of the kidney. (c) Histopathology following hematoxylin-eosin staining revealed the presence of
epidermal, mucous secreting, ciliated epithelial as well as the neuronal tissues. However, there was no evidence of any metastatic lesions in any
other organs. (d) Immunostaining using anti-GFP and anti-C-peptide antibodies revealed the presence of both AcGFP and insulin-positive
transplanted cells.
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ES and iPS cells could potentially overcome the chronic
shortage of cadaveric organs if we are able to establish
efficient differentiation protocols. Derivation of specific
cell types and tissues from ES and iPS cells could end
the need for donated cadaveric tissue. However, the
current protocols for the in vitro differentiation of ES
and iPS cells into IPCs are still very inefficient, time con-
suming and very expensive. Currently, there are two dif-
ferent approaches that allow the generation of IPCs
using ES cells: (a) embryoid body (EB) formation [40]
and (b) definitive endoderm (DE) formation [32]. Here,
we investigated the generation of IPCs using the EBformation approach. The EB represents an early differ-
entiation stage that is characterized by the formation of
a three-dimensional cluster of cells, which give rise to
tissues representing all the three primary germ layers.
A number of differentiation protocols for the gener-
ation of IPCs using ES cells have been reported
[14,27,36,38,41-49]. However, a major caveat is the lack
of pancreatic β-cell-specific surface markers that allow
purification of the IPCs. A second obstacle is that the ES
cell differentiation procedures used are extremely ineffi-
cient. Consequently, in some of these studies, ES cells
could be differentiated into IPCs but their transplant-
ation in diabetic mice seldom led to a correction of the
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production by the ES cell-derived IPCs has been recently
challenged and suggested to be rather an artifact because
the cells could uptake insulin from the culture media
and release it when they apoptose [50,51], leading to
false positive results.
The embryonic development of pancreatic β cells
requires regulated expression of multiple transcription
factors. However, Pdx1 has been shown to be the master
regulator of the pancreas development and plays a cru-
cial role during the development and function of pancre-
atic β cells [16,17,25,28]. Recently, ectopic Pdx1
expression in bone marrow derived mesenchymal stro-
mal cells, human ES cells and adipose tissue derived
stem cells has been demonstrated to promote their dif-
ferentiation into IPCs [26,52-55]. One of the critical
steps in the differentiation of ES cells into IPCs is the
derivation of the Pdx1 expressing pancreatic progenitors.
We, therefore, hypothesized that ectopic over-expression
of Pdx1 in ES cells in vitro enforces lineage commitment
and progressive differentiation of ES cells into IPCs.
Here, we report an alternative approach for the efficient
differentiation of murine ES cells into IPCs. The unique
features about our differentiation strategy are the use of
the pancreatic β-cell-specific transcription factor Pdx1
and the development of a new protocol that eliminates
the nestin selection stage, thus reducing the overall dif-
ferentiation time.
Here, we employed a multistep differentiation strategy
to study and optimize the differentiation of mouse ES
cells into IPCs. The R1Pdx1AcGFP/RIP-Luc ES cell line
was subjected to in vitro differentiation using the EB for-
mation protocol. We compared four different protocols
with modifications post-EB formation for the directed
differentiation of the R1Pdx1AcGFP/RIP-Luc ES cells
into IPCs. The gene expression analysis of the ES cells
undergoing differentiation into IPCs indicates a selective
up-regulation of pancreatic β-cell-specific genes, includ-
ing Pax4, Isl1, insulin 1, insulin 2 and PC2/3, thereby
implying a lineage commitment towards β-cells. These
findings support the view that ES cells can be coaxed to
differentiate into physiologically responsive IPCs. Our
immunostaining results indicate that the ES cells under-
going differentiation express Foxa2, Sox17, Ngn3 and
NeuroD, as well as C-peptide. These results confirm that
our differentiation protocol triggers a temporally regu-
lated signaling cascade mediated by multiple pancreatic
β-cell-specific transcription factors, which ultimately
leads to the robust generation of IPCs. In some cases,
the IPCs are typically arranged in the form of small pan-
creatic islet-like clusters.
Interestingly, despite ectopic Pdx1 expression in our
R1Pdx1AcGFP/RIP-Luc ES cells, we found a significant
number of glucagon-expressing cells in addition to theIPCs. Similar results were observed in transplanted dia-
betic mice following spontaneous in vivo differentiation
of R1Pdx1AcGFP/RIP-Luc ES cell-derived PELCs [32].
However, at present we do not fully understand the mo-
lecular mechanism underlying the generation of gluca-
gon expressing cells in our differentiation studies. Our
results are not entirely surprising because in an earlier
study, inducible biphasic expression of Pdx1 led to the
differentiation of mouse ES cells into both insulin and
glucagon expressing cells [26]. It is possible that sus-
tained Pdx1 expression in our ES cells leads to the de-
velopment of a bihormonal progenitor cell population
during differentiation, which in turn gives rise to both
insulin- and glucagon-expressing cells. These findings
suggest that ectopic Pdx1 expression alone may not be
sufficient to allow for the complete maturation of the
IPCs in vitro. We, however, anticipate that these cells
eventually mature in vivo post-transplantation and be-
come mono-hormonal. In a recent study, adenoviral-
mediated coexpression of Pdx1 and MafA with either
Ngn3 or NeuroD has been shown to improve the gener-
ation of IPCs [56]. However, the critical transplantation
experiments to demonstrate the therapeutic efficacy of
the ES cell-derived IPCs were not performed.
The insulin secretion, as well as glucose responsive-
ness, of the R1Pdx1AcGFP/RIP-Luc ES cell-derived IPCs
was confirmed by an ultrasensitive ELISA. Our ELISA
data suggest that constitutive Pdx1 expression in our
R1Pdx1AcGFP/RIP-Luc ES cell-derived IPCs leads to a
robust glucose responsive insulin secretion as compared
to the biphasic Pdx1 expression or combined inducible
Pdx1 and Ngn3 expression as reported earlier [26,57]. It
is possible that constitutive Pdx1 expression maintains
the insulin processing and secretion mechanism in ES
cell-derived IPCs in a dynamic state, thereby facilitating
glucose responsive insulin secretion. Moreover, in these
earlier studies, the much needed transplantation experi-
ments to evaluate the therapeutic efficacy of ES cell-
derived IPCs to correct hyperglycemia in diabetic mice
were not performed.
The therapeutic efficacy of the IPCs derived using our
new differentiation protocol was tested in streptozotocin-
treated 129/SvJ syngeneic diabetic mice by transplanting
the cells under the kidney capsule. The 129/SvJ mice
administered STZ for five consecutive days become pro-
gressively diabetic, do not recover from severe hypergly-
cemia and die between Days 10 and 15 due to failure of
endogenous β-cell regeneration as reported earlier [32].
In the present studies, R1Pdx1AcGFP/RIP-Luc ES cell-
derived IPCs were transplanted under the kidney capsule
of the syngeneic 129/SvJ diabetic mice. The blood glucose
levels in mice transplanted with the IPCs demonstrated a
steady decline until Day 20 when they finally stabilized
throughout the duration of the study. However, complete
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planted mice. We speculate that the base-line hypergly-
cemia could easily be overcome by transplanting a greater
number of IPCs. To further validate our results, we per-
formed immunofluorescence analysis of the kidney that
was transplanted with the IPCs. Our immunofluorescence
data demonstrate the presence of positive insulin staining
of the R1Pdx1AcGFP/RIP-Luc ES cell-derived IPCs in the
kidney. Our results confirm that the transplanted IPCs
were functional and able to correct hyperglycemia.
Thus, our studies highlight the need to develop novel
strategies to selectively enrich IPCs by eliminating the
tumor-causing cells prior to transplantation. Possible can-
didate cell surface molecules that could be used to remove
non-differentiated and partially differentiated ES cells are
CXCR4, CD326 and surface specific early antigen.
Conclusions
Our current studies demonstrate the potential for pluri-
potent stem cell-based treatment of type 1 diabetes by
enhanced generation of IPCs from ES cells. Although we
achieved high level insulin secretion by our newly estab-
lished protocol, we believe that ectopic Pdx1 expression
in our ES cells alone may not be sufficient to robustly
generate IPCs. Our studies also demonstrate the poten-
tial utility of real-time noninvasive BLI to monitor the
in vivo fate of transplanted IPCs. Finally, our studies
provide evidence that for more efficient application of
ES cells in the treatment of diabetes we will need to be
able to separate teratogenic non-differentiated ES cells
from fully differentiated IPCs. While much remains to
be done, ES and the iPS cells have the potential to be-
come a new renewable source of IPCs that could allevi-
ate the chronic shortage of pancreatic islets for the
treatment of type 1 diabetes.
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